Eptinezumab — Membership Pricing

Other medications in Neurological

• Erenumab
• Eslicarbazepine
• Felbamate
• Fenfluramine
• Fingolimod
• Fosphenytoin
• Fremanezumab
• Galantamine

About Eptinezumab

Eptinezumab, marketed as Vyepti, represents a significant advancement in the preventive treatment of migraine in adults. Administered as a quarterly intravenous infusion, it offers a consistent approach to reducing migraine frequency and severity. At TheDrugClub, we understand the financial considerations of specialty medications and strive to help our members find pathways to potential savings on treatments like eptinezumab.

Eptinezumab (Vyepti) is an innovative medication specifically approved for the preventive treatment of migraine in adults. This includes individuals suffering from both episodic and chronic migraine, offering a new avenue for those who have not found adequate relief with other preventive therapies. Migraine is a debilitating neurological disorder characterized by severe headaches, often accompanied by symptoms such as throbbing pain, nausea, vomiting, and extreme sensitivity to light and sound. By reducing the frequency and intensity of these attacks, eptinezumab can significantly improve a patient's quality of life.

So, how does eptinezumab work its magic? It belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) antagonists. CGRP is a neuropeptide found throughout the body, and it plays a crucial role in the pain pathways associated with migraine. During a migraine attack, CGRP levels increase, contributing to the inflammation and pain signals in the brain.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Eptinezumab is approved for (FDA label)

VYEPTI is indicated for the preventive treatment of migraine in adults. VYEPTI is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: June 5, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Eptinezumab (FDA label)

VYEPTI is a clear to slightly opalescent, colorless to brownish-yellow solution available as follows: Injection: 100 mg/mL in a single-dose vial Injection: 100 mg/mL solution in a single-dose vial ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 79065861-6aa5-4d1f-829f-3a6471286b36. SPL document ID: ae1b6705-69c6-4f31-8017-2a3abc032d53. Label effective date: June 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Eptinezumab (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] . Constipation with Serious Complications [see Warnings and Precautions (5.2)] Hypertension [see Warnings and Precautions (5.3) ] Raynaud’s Phenomenon [see Warnings and Precautions (5.4) ] The most common adverse reactions (≥2% and 2% or greater than placebo) were nasopharyngitis and hypersensitivity ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 79065861-6aa5-4d1f-829f-3a6471286b36. SPL document ID: ae1b6705-69c6-4f31-8017-2a3abc032d53. Label effective date: June 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Eptinezumab (FDA label)

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients in VYEPTI. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.1) ] . VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients ( 4)

Source: FDA prescribing information (DailyMed). Set ID: 79065861-6aa5-4d1f-829f-3a6471286b36. SPL document ID: ae1b6705-69c6-4f31-8017-2a3abc032d53. Label effective date: June 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Eptinezumab (FDA label)

Hypersensitivity Reactions: If a hypersensitivity reaction occurs, consider discontinuing VYEPTI and initiate appropriate therapy ( 5.1 ) Constipation with Serious Complications: Serious complications of constipation may occur ( 5.2 ) Hypertension: New-onset or worsening of pre-existing hypertension may occur ( 5.3 ) Raynaud’s Phenomenon: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur ( 5.4 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting.

Source: FDA prescribing information (DailyMed). Set ID: 79065861-6aa5-4d1f-829f-3a6471286b36. SPL document ID: ae1b6705-69c6-4f31-8017-2a3abc032d53. Label effective date: June 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.